Forbion is a leading European life sciences venture capital firm that works closely with entrepreneurs to build life sciences companies that transform people’s lives.
Forbion helps companies bridge research and development through the team’s expertise in drug development and company building.
Forbion was co-founded in 2006 by Sander Slootweg, Martien van Osch and Geert-Jan Mulder. The firm is headquartered in Naarden, Netherlands, with offices in Germany and Singapore.
Forbion is a signatory to the United Nations Principles for Responsible Investment further demonstrating its philosophy that investments in companies should positively impact the health and well-being of patients.
Forbion’s investors include the European Investment Fund (EIF), notably through its European Recovery Programme (ERP), LfA, the Dutch Venture Initiative (DVI) and AMUF facilities, and the Kreditanstalt für Wiederaufbau (KFW) through the ERP – Venture Capital Fondsfinanzierung facility.
Forbion announced the first close of Forbion Growth Opportunities Fund II at €470M on Nov 09, 2022. The fund will be focused on investing in late-stage European life sciences companies. The company raised €360M for its Fund I in early 2020.
Forbion currently manages over €2 bn across ten closed-end funds. Forbion has more than 30 active portfolio companies, including AMT, Acadia Pharmaceuticals, Acorda Therapeutics, Bluebird Bio, Anaveon, ARMGO Pharma, and enGene.